Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Autor: James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gert, Brawley, Chris D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Montana, Carlos Diaz, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominic R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W.S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob, Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K.B., Sydes, Matthew R.

Publikováno v: James, N D, Clarke, N W, Cook, A, Ali, A, Hoyle, A P, Attard, G, Brawley, C D, Chowdhury, S, Cross, W R, Dearnaley, D P, Bono, J S, Montana, C D, Gilbert, D, Gillessen, S, Gilson, C, Jones, R J, Langley, R E, Malik, Z I, Matheson, D J, Millman, R, Parker, C C, Pugh, C, Rush, H, Russell, J M, Berthold, D R, Buckner, M L, Mason, M D, Ritchie, A WS, Birtle, A J, Brock, S J, Das, P, Ford, D, Gale, J, Grant, W, Gray, E K, Hoskin, P, Khan, M M, Manetta, C, McPhail, N J, O'Sullivan, J M, Parikh, O, Perna, C, Pezaro, C J, Protheroe, A S, Robinson, A J, Rudman, S M, Sheehan, D J, Srihari, N N, Syndikus, I, Tanguay, J, Thomas, C W, Vengalil, S, Wagstaff, J, Wylie, J P, Parmar, M KB & Sydes, M R 2022, ' Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) ', International Journal of Cancer . https://doi.org/10.1002/ijc.34018

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multi-arm, multi-stage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d41e4f972431efac3e44597e81d1a4a
https://pure.qub.ac.uk/en/publications/3adddebe-1d1a-4134-8495-5f087a1fee9e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abiraterone in 'High-' and 'Low-risk' Metastatic Hormone-sensitive Prostate Cancer

Autor: Hoyle, Alex P, Ali, Adnan, James, Nicholas D, Cook, Adrian, Parker, Christopher C, De Bono, Johann S, Attard, Gerhardt, Chowdhury, Simon, Cross, William R, Dearnaley, David P, Brawley, Christopher D, Gilson, Clare, Ingleby, Fiona, Gillessen, Silke, Aebersold, Daniel, Jones, Rob J, Matheson, David, Millman, Robin, Mason, Malcolm D, Ritchie, Alastair W S, Russell, Martin, Douis, Hassan, Parmar, Mahesh K B, Sydes, Matthew R, Clarke, Noel W

BACKGROUND Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::602388fa39b3dcf38e51c81173332512